Company / SG&A Expense
AbCellera Biologics Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$83.2M
FY2025
5-year range
$2.7M / $85.5M
FY2021-FY2025
Trend
-2.6%
vs FY2024
Sector context
#123 of 213
Health Care
What the data says
At $83M, AbCellera Biologics Inc.'s sg&a expense ranks #91 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 7 years, ranging from $3M in FY2021 to $85M in FY2024.
Based on SEC 10-K filings.
$83M in FY2025 with a 5-year CAGR of +47.5%.
Increased from $75M to $83M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +91.2%
- 5-Year CAGR
- +47.5%
- 10-Year CAGR
- -
Sector benchmark
#91 of 213 in Health CareTop 42% of 213This company $83.2M Sector average $722.3M
▼
-88.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +47.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.6% year-over-year.
- Ranks #123 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $83.2M | -2.6% |
| FY2024 | $85.5M | +13.7% |
| FY2023 | $75.2M | +531.2% |
| FY2022 | $11.9M | +333.2% |
| FY2021 | $2.7M | -76.9% |
| FY2020 | $11.9M | +333.2% |
| FY2019 | $2.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026